Myeloid Leukemia is an aggressive (fast-growing) disease in which too many myeloblasts (immature white blood cells that are not lymphoblasts) are found in the bone marrow and blood. Also called acute myeloblastic leukemia, acute myelogenous leukemia, acute nonlymphocytic leukemia, AML, and ANLL.
In the first comprehensive analysis of clinical trial enrollment among older adults with blood cancers, researchers from the U.S. Food and Drug Administration found significant gaps in participation among those aged 75 and older when considered against the incidence of these malignancies in this age group, according to research being presented today during the 59th American Society of Hematology Annual Meeting and Exposition in Atlanta.
Initial findings from a multi-national open-label phase Ib study of inhibitory drug therapy for relapsed or refractory acute myeloid leukemia (AML) have demonstrated a complete response in up to 50 percent patients say researchers at The University of Texas MD Anderson Cancer Center.
University of North Carolina Lineberger Comprehensive Cancer Center researchers report that pairing an immunotherapy drug with chemotherapy proved beneficial for some patients with acute myeloid leukemia whose disease did not respond to standard treatment or had relapsed.
A clinical trial using genetic testing to match acute myeloid leukemia (AML) patients with new therapies is now open at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
The Independent Citizens Oversight Committee of the California Institute for Regenerative Medicine unanimously approved yesterday two grants worth a total of almost $8 million to University of California San Diego School of Medicine researchers investigating novel stem cell-based treatments for acute myeloid leukemia or AML.
Patients diagnosed with the most common form of leukemia who also have high levels of an enzyme known to suppress the immune system are most likely to die early, researchers say.
Researchers at Fred Hutchinson Cancer Research Center and the University of Washington have developed a novel way to genetically engineer T cells that may be effective for treating and preventing leukemia relapse.
Killing cancer cells indirectly by powering up fat cells in the bone marrow could help acute myeloid leukemia patients, according to a new study from McMaster University.
Developing new drugs to treat cancer can be a painstaking process taking over a decade from start to Food and Drug Administration approval. Scientists are trying to develop innovative strategies to identify and test new drugs quicker and more efficiently.
Researchers have discovered a compound that can trigger cancer cells to self-destruct, without causing any damage to healthy cells.
Scientists at Albert Einstein College of Medicine have discovered the first compound that directly makes cancer cells commit suicide while sparing healthy cells.
New research published today uncovers how the blood cancer 'steals' parts of surrounding healthy bone marrow cells to thrive, in work that could help form new approaches to cancer treatment in the future.
A genetic fault has been identified in people with an aggressive type of leukemia that can significantly affect how they respond to treatment.
Two drugs, already approved for safe use in people, may be able to improve therapy for chronic myeloid leukemia (CML), a blood cancer that affects myeloid cells, according to results from a University of Iowa study in mice.
On the advent of the 2017 Head and Neck Cancer Awareness Week, the European Cancer Patient Coalition invited patients and policy makers to gather at the European Parliament to promote better quality of life for cancer patients and survivors as part of the Make Sense Campaign.
A chemically modified version of the common blood thinner heparin may be the first promising method of preventing the harmful cascade of destruction to brain tissue that commonly follows traumatic brain injury (TBI), according to new research findings.
The U.S. Food and Drug Administration today approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed acute myeloid leukemia whose tumors express the CD33 antigen (CD33-positive AML).
Pfizer Inc. today announced that the U.S. Food and Drug Administration approved MYLOTARG (gemtuzumab ozogamicin) for adults with newly diagnosed CD33-positive acute myeloid leukemia (AML), and adults and children 2 years and older with relapsed or refractory CD33-positive AML.
A UK leukemia charity, Leukaemia CARE, has launched the Spot Leukaemia campaign to raise awareness of the signs and symptoms of leukemia after a survey revealed that leukemia diagnoses are commonly delayed due to poor understanding.
The newly established research program, 'Program for Translational Hematology', has just received DKK 100 million in funding from the Novo Nordisk Foundation.